Expression of NOS and VEGF in feline mammary tumours and their correlation with angiogenesis.

In order to define the role of nitric oxide (NO) in feline mammary tumours, the expression of endothelial or inducible nitric oxide synthase (e/iNOS) and vascular endothelial growth factor (VEGF), and their relationship with angiogenesis, was investigated in 23 feline mammary tumours (two hyperplastic, 19 adenocarcinoma, one osteosarcoma and one squamous cell carcinoma) by immunohistochemistry. Tumour angiogenesis was assessed by CD31 immunostaining and was expressed as microvessel density (MVD). In general, iNOS immunoreactivity was localised in tumour cells and occasionally in stromal myofibroblasts, whereas eNOS and VEGF were localised in the cytoplasm of tumour epithelial cells and endothelium. In malignancy, expression of iNOS increased from well- to less-differentiated phenotypes (Grades 1-3) and was significantly higher in G3 and G2 when compared with G1 cases. However, increasing eNOS expression was limited only in hyperplastic lesions and showed no significant changes among the grades. In addition, expression of iNOS was positively correlated with VEGF and MVD in feline mammary tumours and both measures were significantly greater in less differentiated phenotypes (P<0.05). In conclusion, the expression of NOS isoforms in feline mammary tumours depended on tumour grade, and the positive correlations between iNOS and angiogenic markers suggests that iNOS synthesised by tumour cells promotes tumour growth. Thus, iNOS can be used as an important immunohistochemical marker to determine the degree of malignancy and prognosis of feline mammary carcinoma.

Small hepatocellular carcinoma with intravascular tumor growth into the right atrium.

A 66-year-old man with ascites and marked edema in the lower extremities was suspected of having secondary Budd-Chiari syndrome due to primary liver cancer, based on imaging diagnosis, i.e., ultrasonography, computed tomography, and inferior venacavogram. At autopsy, an encapsulated small liver cancer was found to have extended into the inferior vena cava and right atrium. There have been few reports of small hepatocellular carcinoma with intravascular tumor growth into the right atrium.

Sarcoidosis accompanied by pancreatic impairment.

A 64-year-old male complained of weight loss and slight fever. Bilateral hilar lymphadenopathy and hepato-splenomegaly were observed. Serum ACE level was high, and liver function was impaired. Laparoscopy demonstrated small white nodules on the liver surface. A definite diagnosis of sarcoidosis was made by histological study of the specimen by liver biopsy and noncaseating epithelioid cell granulomas composed of giant cells and epithelioid cells were revealed. Various pancreatic enzymes were increased on admission, suggesting pancreatic impairment due to sarcoidosis. Corticosteroid therapy improved liver and pancreatic functions and decreased splenomegaly. He has been followed up for 4 years and 5 months.

[Tissue levels of bleomycin administered as suppository].

We prepared a bleomycin suppository, aiming not only at allowing bleomycin to be transferred into the malignant tumor tissue of the intrapelvic organs and their regional lymph nodes at high levels but also at preventing transient elevation of its level in the blood. This administration route might be effective on the primary lesions of urogenital malignant tumors and their metastases to the regional lymph nodes, and prevent systemic adverse reactions. To prove these effects, we determined the levels of bleomycin in the tissue, blood, lymph nodes, urine and stools following intrarectal application of the bleomycin suppository. The pattern of bleomycin uptake by the intrapelvic tissues showed that the drug was retained by tumor tissue at high levels for a long time, compared with that by the normal tissue. Its levels in the blood suggested the reduction in systemic adverse reactions. Its uptake by the regional lymph nodes was unexpectedly low, but this may be attributed to an early collection of the tissue after the application. We think it necessary to follow up changes in bleomycin level in the tissues collected at predetermined intervals.